Artificial antibodies created by new molecular imprinting process

July 24, 2002

CHAMPAIGN, Ill. -- Nature is especially adept at producing molecules that can recognize and bind other molecules. For example, antibody molecules will search out and bind a single foreign molecule, called an antigen, from among myriad other natural substances. This type of exquisite molecular recognition has long inspired chemists, who for decades have tried to make molecules that are capable of performing similar feats.

Now, a team of chemists at the University of Illinois at Urbana-Champaign, led by professors Steven C. Zimmerman and Kenneth S. Suslick, has developed a way of creating artificial antibodies. The process -- which they describe in the July 25 issue of the journal Nature -- is a general approach wherein one molecule imprints its structure within a larger host molecule, in much the same way an object can cast its own shape in plaster of paris.

"This is the first example of molecular imprinting in which a single molecular template is imprinted into a single macromolecule -- a highly branched polymer called a dendrimer," said Zimmerman, a William H. and Janet Lycan Professor of Chemistry at Illinois. "Upon removal of the template, we have a synthetic molecular shell that can bind specifically shaped molecules and reject all others, just like a natural antibody."

The process Zimmerman and Suslick describe is analogous to Linus Pauling's 1940 proposal for how antibodies are formed in response to the presence of an antigen. Although Pauling's mechanism proved to be incorrect, it inspired considerable experimental work, which ultimately led to the modern field of polymer imprinting.

One disadvantage of conventional polymer imprinting is that each "antigen" or template molecule produces an artificial antibody containing all kinds of different binding sites, most of which have poor recognition abilities and are therefore ineffective.

"Using dendrimers for imprinting one molecule against another is much faster and more efficient," Zimmerman said. "And, having a single binding site within a single polymer means we can more easily separate the good imprints from the bad."

To make their molecular molds, the researchers begin by attaching wedge-shaped molecules called dendrons to a porphyrin core to create a dendrimer. The flexible dendrimer scaffolding is then cross-linked in a chemical reaction that stitches together the end-groups of the dendrons. Lastly, a hydrolysis reaction chemically clips out the core, leaving a hollow space that can selectively and tightly bind appropriately shaped molecules.

"The technique is similar to the lost wax process used in metal casting," said Suslick, also a William H. and Janet Lycan Professor of Chemistry at Illinois. "In essence, we are molding this dendrimer around our template and creating a rigid cast that functions like a molecular lock for a molecular key."

The technique should be applicable to many molecules and a host of molecular recognition tasks. Potential applications include organic catalysts, medical diagnostics, and sensors for various pollutants and chemical warfare agents.

"Right now, we have a conceptual advance," Zimmerman said. "We've shown there's a new approach that can imprint a single molecule within a single molecule. Ultimately, we envision taking a template, and in a single step growing the scaffolding that can then be linked together to make a rigid mold."
In addition to Zimmerman and Suslick, collaborators on the project were graduate students Michael Wendland and Neal Rakow (both now at 3M) and Ilya Zharov, a postdoctoral research associate at the university's Beckman Institute for Advanced Science and Technology. The National Institutes of Health and the U.S. Army Research Office funded the work.

University of Illinois at Urbana-Champaign

Related Antibodies Articles from Brightsurf:

Scientist develops new way to test for COVID-19 antibodies
New research details how a cell-free test rapidly detects COVID-19 neutralizing antibodies and could aid in vaccine testing and drug discovery efforts.

Mussels connect antibodies to treat cancer
POSTECH research team develops innovative local anticancer immunotherapy technology using mussel protein.

For an effective COVID vaccine, look beyond antibodies to T-cells
Most vaccine developers are aiming solely for a robust antibody response against the SARS-CoV-2 virus, despite evidence that antibodies are not the body's primary protective response to infection by coronaviruses, says Marc Hellerstein of UC Berkeley.

Children can have COVID-19 antibodies and virus in their system simultaneously
With many questions remaining around how children spread COVID-19, Children's National Hospital researchers set out to improve the understanding of how long it takes pediatric patients with the virus to clear it from their systems, and at what point they start to make antibodies that work against the coronavirus.

The behavior of therapeutic antibodies in immunotherapy
Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies are used to stop the proliferation of cancerous white blood cells.

Re-engineering antibodies for COVID-19
Catholic University of America researcher uses 'in silico' analysis to fast-track passive immunity

Seroprevalence of antibodies to SARS-CoV-2 in 10 US sites
This study estimates how common SARS-CoV-2 antibodies are in convenience samples from 10 geographic sites in the United States.

Neutralizing antibodies in the battle against COVID-19
An important line of defense against SARS-CoV-2 is the formation of neutralizing antibodies.

Three new studies identify neutralizing antibodies against SARS-CoV-2
A trio of papers describes several newly discovered human antibodies that target the SARS-CoV-2 virus, isolated from survivors of SARS-CoV-2 and SARS-CoV infection.

More effective human antibodies possible with chicken cells
Antibodies for potential use as medicines can be made rapidly in chicken cells grown in laboratories.

Read More: Antibodies News and Antibodies Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to